Discover & Learn

Discover how our end-to-end radiopharmacy solutions can support your production goals.

Our team is ready to discuss cyclotron and radiochemistry technologies, as well as comprehensive integrated solutions for efficient and reliable radiopharmaceutical production.

Take the chance to exchange on current projects, technical challenges, and future plans.

Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued progress towards its profitability improvement trajectory. The period was marked by strong commercial momentum, notably in Proton Therapy and RadioPharma Solutions, as well as the strengthening of IBA’s leadership team and Board to support the Group’s growth and execution of its strategic roadmap.

Fluorine-18: half-life of 110 minutes. Gallium-68: 68 minutes. Astatine-211: 7.2 hours. Lutetium-177: 6.7 days.

Even for the longer-lived isotopes, every hour between production and injection is activity lost, meaning dose delivered to the patient decreases.

For the short-lived isotopes, the window is brutal. A [⁶⁸Ga]-labelled radiopharmaceutical produced at 7.00 AM may be largely unusable by 11.00 AM. A [¹⁸F]-labelled dose that leaves the production facility late due to a quality control delay may not meet specifications when it arrives at the hospital.

This is not a manufacturing problem that can be solved by producing more batches. It is a fundamental physical constraint that the entire supply chain must be designed around.
 

Radiometals are metallic radionuclides, radioactive isotopes of metallic elements, used in the production of radiopharmaceuticals for imaging or therapy.

Unlike Fluorine-18 ([¹⁸F]), the well-established for PET imaging, which is covalently bonded directly into small organic molecules and enters metabolic pathways, radiometals cannot simply be incorporated into a molecule through organic chemistry.

They require a chelator, a bifunctional molecule that has two functional ends: one that tightly binds the radiometal, and one that can be conjugated to a targeting vector (a peptide, antibody, nanobody, or another molecule).

The chelator acts as a molecular harness. It keeps the radiometal attached to the targeting vector throughout the journey to target.

Getting the chelation chemistry right is as important as choosing the right radiometal. Instability leads to off-target uptake in organs, increased toxicity, and reduced diagnostic or therapeutic efficacy.

An alpha particle is a helium nucleus — two protons and two neutrons, tightly bound together. Compared with other forms of ionizing radiation, it is relatively massive and carries a double positive charge.

That combination of mass and charge makes alpha particles interact very intensely with the matter they travel through. They lose energy rapidly, which is why their range in tissue is so short. And as they lose that energy, they deposit it in a very dense track of ionization events along an extremely short path.

The result is an extraordinarily high Linear Energy Transfer (LET), the amount of energy deposited per unit of distance travelled.

Alpha particles have a LET hundreds of times higher than that of beta-emitting radionuclides such as Lutetium-177.

In practice, that means alpha particles cause DNA double-strand breaks (DSBs), the most difficult form of DNA damage a cell can sustain. Unlike single-strand breaks, which the cell's repair machinery can often fix, double-strand breaks are very difficult to repair correctly. The cells typically cannot survive them.
 

Targeted Radionuclide Therapy, Radiotheranostics and Targeted Alpha Therapy, 3 terms that are constantly confused, even by people inside the field, but they have different meanings.